Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:54 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 2,021 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Initial Surgery Clear all
Completed Phase 2 Interventional Results available

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT01104922
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Cetuximab, Stereotactic radiosurgery
Drug · Device
Lead sponsor
David A. Clump, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Nov 3, 2026, 4:54 AM EST
Completed Not applicable Interventional

Binocular Treatment of Amblyopia Before and After Strabismus Surgery

NCT01791946
View directory record Official record
Conditions
Amblyopia, Strabismus
Interventions
Binocular Treatment, Sham Binocular Treatment
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Nov 3, 2026, 4:54 AM EST
Completed Not applicable Interventional Results available

Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers

NCT06557122
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
SOC and Advanced Bioengineered Skin Substitute, SOC and Active Comparator
Device · Other
Lead sponsor
Encoll Corp
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Angeles, California • South Miami, Florida • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Nov 3, 2026, 4:54 AM EST
Recruiting Phase 1 Interventional

FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

NCT07645469
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Multigated Acquisition Scan, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 4:54 AM EST
Terminated Phase 2 Interventional Results available

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

NCT02994251
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Nov 3, 2026, 4:54 AM EST
Completed Phase 2 Interventional Results available

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

NCT02904954
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Durvalumab plus SBRT
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Nov 3, 2026, 4:54 AM EST
Active, not recruiting Phase 2 Interventional Results available

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

NCT04284787
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab, Venetoclax
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
29
States / cities
Greenwich, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 3, 2026, 4:54 AM EST
Completed Phase 4 Interventional Results available

Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

NCT05391893
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Oral, Intravenous drug
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 3, 2026, 4:54 AM EST
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Nov 3, 2026, 4:54 AM EST
Terminated Not applicable Interventional Results available

Treatment of Sickle Cell Anemia With Stem Cell Transplant

NCT01350232
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
Interventions
Fludarabine, Cytarabine, Cellular Infusions, Total Body Irradiation, Cyclophosphamide, Bortezomib, Rituximab, Plasmapheresis
Drug · Device · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Nov 3, 2026, 4:54 AM EST
Recruiting No phase listed Observational

Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)

NCT06960798
View directory record Official record
Conditions
Prostate Cancer, Renal Cell Carcinoma (RCC)
Interventions
Bio-specimen Collection, Blood Draw
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 4:54 AM EST
Completed Not applicable Interventional

Feasibility Bowel Dysfunction Program After Low Anterior Resection

NCT04733794
View directory record Official record
Conditions
Rectal Cancer, Low Anterior Resection
Interventions
Stoma reversal
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Nov 3, 2026, 4:54 AM EST
Completed No phase listed Observational

Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.

NCT02781272
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
Procedure
Lead sponsor
Angle plc
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Nov 3, 2026, 4:54 AM EST
Not listed Not applicable Interventional

On-Table Versus Off-Table Total Hip Arthroplasty

NCT04831372
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip, Osteoarthritis, Hip
Interventions
Off Table Group, On Table Group
Procedure
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Nov 3, 2026, 4:54 AM EST
Active, not recruiting Phase 1 Interventional

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT04572451
View directory record Official record
Conditions
Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
Interventions
nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 3, 2026, 4:54 AM EST
Terminated Phase 2 Interventional Results available

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

NCT03871153
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Interventions
Durvalumab, Paclitaxel, Carboplatin, Radiation, Surgical Resection
Device · Drug · Radiation + 1 more
Lead sponsor
Greg Durm, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Nov 3, 2026, 4:54 AM EST
Terminated Phase 4 Interventional Results available

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

NCT03361137
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Nov 3, 2026, 4:54 AM EST
Terminated Phase 1Phase 2 Interventional

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201

NCT06078566
View directory record Official record
Conditions
Microtia
Interventions
AUR-201
Combination Product
Lead sponsor
Auregen Biotherapeutics, SA
Industry
Eligibility
8 Years to 29 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 3, 2026, 4:54 AM EST
Completed Phase 1 Interventional

Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors

NCT02458339
View directory record Official record
Conditions
Brain Tumor, Recurrent, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions
Ommaya Reservoir, Methotrexate
Procedure · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Nov 3, 2026, 4:54 AM EST
Active, not recruiting Not applicable Interventional

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

NCT03747393
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
DoD/VA CPG Core Set + PT, DoD/VA CPG Core Set
Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 3, 2026, 4:54 AM EST
Terminated Phase 4 Interventional Results available

TXA in Revision Total Shoulder Arthroplasty

NCT04650698
View directory record Official record
Conditions
Arthropathy Shoulder
Interventions
Tranexamic acid (TXA) injection
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Nov 3, 2026, 4:54 AM EST
Completed Not applicable Interventional Results available

Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members

NCT03611309
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Surgeon-palliative care team co management, Surgeon team alone management
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 3, 2026, 4:54 AM EST
Terminated Phase 2 Interventional

LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

NCT00260598
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer, Pulmonary Disease, Chronic Obstructive
Interventions
LIFE Bronchoscopy
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Nov 3, 2026, 4:54 AM EST